$NKTR BULLISH PRICE ACTION PREEMPTS TRIAL DATA

The stock of NKTR has been setting up nicely for a breakout and June 13th could be the day it happens, as the company will be hosting a analysts conference call to discuss trial results/data. Keep on strong watch for explosive moves.

AVERAGE ANALYSTS PRICE TARGET $69.50
AVERAGE ANALYSTS RECOMMENDATION OVERWEIGHT
SHORT INTEREST 12.65%
P/E RATIO 9.54

Nektar Therapeutics (NKTR -0.6%) will host a conference call for analysts and investors on Thursday, June 13, at 8:00 am ET to discuss Phase 1a data on NKTR-358 in healthy volunteers. The results will be presented at EULAR in Madrid. NKTR-358 is a regulatory T cell stimulator in development for autoimmune disorders.


COMPANY PROFILE
Nektar Therapeutics is a biopharmaceutical company, which engages in applying technology platforms to develop novel drug candidates. The company focuses on the therapies for cancer, autoimmune disease, and chronic pain. It operates through the United States and Europe geographical segments. The company was founded in 1990 and is headquartered in San Francisco, CA.